Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Graft versus host disease (GVHD) is one of the common complications after stem cell
transplant. This is a complication, which happens when the new stem cells from the donor
attack other cells in the body of the transplant recipient.
Recently, an antibody (protein) called alemtuzumab or Campath has been found to be effective
in the prevention of Graft vs. Host Disease.
Previous studies have shown a low risk of GVHD with alemtuzumab, however the risk of disease
recurrence was high. Previous studies have used a high dose of alemtuzumab. The purpose of
this study is:
- To find if by lowering the dose of alemtuzumab, can serious GVHD be prevented without
increasing the risk of relapse (your condition getting worse).
- To find whether low dose of alemtuzumab in combination with cyclosporine can prevent
GVHD more effectively when compared to current standard of care and does not increase
the risk of recurrence.